# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Raymond James analyst David Novak maintains Knight Therapeutics (OTC:KHTRF) with a Outperform and raises the price target fr...
Knight Therapeutics Inc. (TSX: GUD) (OTC: KHTRF)